New hope for scarred bone marrow: drug trial aims to make transplants safer
NCT ID NCT07471503
Summary
This study is testing whether adding the drug Gecacitinib before, during, and after a stem cell transplant can help people with myelofibrosis, a serious bone marrow disease. The main goal is to see if the drug helps patients survive the first year after transplant without their disease coming back and without severe complications from the transplant itself. It will involve 39 adults with intermediate or high-risk disease who are scheduled for a donor stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS，MF are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.